Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Operating Expenses (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Operating Expenses for 11 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 22.1% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.6 million, a 25.48% increase, with the full-year FY2024 number at $17.7 million, down 1.02% from a year prior.
  • Operating Expenses was $3.4 million for Q3 2025 at Marker Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.0 million in Q4 2021 to a low of $3.4 million in Q3 2025.
  • A 5-year average of $6.4 million and a median of $5.1 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 59.86% in 2021, then plummeted 68.48% in 2023.
  • Marker Therapeutics' Operating Expenses stood at $11.0 million in 2021, then tumbled by 65.49% to $3.8 million in 2022, then increased by 5.17% to $4.0 million in 2023, then skyrocketed by 53.05% to $6.1 million in 2024, then crashed by 44.88% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Operating Expenses are $3.4 million (Q3 2025), $5.1 million (Q2 2025), and $5.0 million (Q1 2025).